Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does USTEKINUMAB Cause Therapeutic response decreased? 1,224 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 1,224 reports of Therapeutic response decreased have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 1.4% of all adverse event reports for USTEKINUMAB.

1,224
Reports of Therapeutic response decreased with USTEKINUMAB
1.4%
of all USTEKINUMAB reports
102
Deaths
250
Hospitalizations

How Dangerous Is Therapeutic response decreased From USTEKINUMAB?

Of the 1,224 reports, 102 (8.3%) resulted in death, 250 (20.4%) required hospitalization, and 211 (17.2%) were considered life-threatening.

Is Therapeutic response decreased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 1,224 reports have been filed with the FAERS database.

What Other Side Effects Does USTEKINUMAB Cause?

Drug ineffective (12,471) Off label use (10,990) Product dose omission issue (9,405) Fatigue (5,457) Product use issue (5,008) Psoriasis (4,955) Pain (4,872) Rash (4,736) Crohn's disease (4,662) Arthralgia (4,608)

What Other Drugs Cause Therapeutic response decreased?

DUPILUMAB (7,824) ETANERCEPT (3,460) ONABOTULINUMTOXINA (2,685) METHOTREXATE (2,668) INFLIXIMAB (1,991) RITUXIMAB (1,728) LEFLUNOMIDE (1,574) TOCILIZUMAB (1,512) HYDROXYCHLOROQUINE (1,485) ADALIMUMAB (1,357)

Which USTEKINUMAB Alternatives Have Lower Therapeutic response decreased Risk?

USTEKINUMAB vs USTEKINUMAB-STBA USTEKINUMAB vs VADADUSTAT USTEKINUMAB vs VALACYCLOVIR USTEKINUMAB vs VALBENAZINE USTEKINUMAB vs VALBENAZINE DITOSYLATE

Related Pages

USTEKINUMAB Full Profile All Therapeutic response decreased Reports All Drugs Causing Therapeutic response decreased USTEKINUMAB Demographics